Premium
Highly selective SYK inhibitor, GSK 143, abrogates survival signals in chronic lymphocytic leukaemia
Author(s) -
Varghese Abraham M.,
Rawstron Andy,
Newton Darren,
Tooze Reuben M.,
Munir Talha,
Dickson Marion,
Doody Gina M.,
Hillmen Peter
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14884
Subject(s) - syk , lyn , cancer research , chronic lymphocytic leukemia , chemistry , tyrosine kinase , kinase , idelalisib , pi3k/akt/mtor pathway , medicine , pharmacology , immunology , leukemia , signal transduction , ibrutinib , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom